Organization | Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA

Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2020

NCT04403100

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Cardresearch | Cardresearch - Cardiologia Assistencial e de Pesquisa | Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA

Active Ingredients

Drugs in Phase 3 Trials (9)

doxazosin (cardura) (1 trial)

fluvoxamine (luvox) (2 trials)

hydroxychloroquine (plaquenil) (1 trial)

interferon beta-1a (Avonex) (1 trial)

ivermectin (stromectol) (1 trial)

lopinavir (Kaletra) (1 trial)

metformin (glucophage) (1 trial)

peginterferon lambda-1a (1 trial)

ritonavir (Norvir) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 3)

Coronavirus Infections (Phase 3)

Infections (Phase 3)

Respiratory Tract Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Virus Diseases (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 9